glp-1 ibd More encouraging news about medications. New research presented at ASCO found that patients with inflammatory bowel disease (IBD) who used GLP- 1 receptor agonists had a 51% lower odds of developing colorectal GLP-1 agonists in IBD: a

It is crucial to consult a healthcare provider before starting any new supplement, especially for individuals with pre-existing medical conditions or those taking other medications, to ensure safety and appropriateness

This is an important finding because it suggests that the GLP-1 system does play a direct role in anxiety regulation, not just an indirect one

Front Immunol 12:797302 Kato M et al (2018) Clostridium butyricum MIYAIRI 588 increases the lifespan and multiple-stress resistance of Caenorhabditis elegans

For example, in one study, GLP-1/GIP weight loss program showed extremely similar results to its Ozempic counterpart by helping obese participants lose 20% or more of their starting weight

Thus, we suggest that one single application of the NO-synthase (NOS) blocker N(G)-nitro-L-arginine methyl ester (L-NAME) may induce retinal ischemia in rats, and that the stable pentadecapeptide BPC 157 may be the therapy, since it may interact with the NO-system and may counteract various adverse effects of L-NAME application (see Wu et al., 2020) [i.e., activation of the VEGFR2-Akt-eNOS signaling pathway without the need of other known ligands or shear stress ( In the previous eye research studies, BPC 157 counteracts atropine-mydriasis, but it also opposes an immediate and hour-lasting miotic effect of L-NAME in rats and guinea pigs, and participates in pupil control potentially via NO-mediated and cholinergic mechanisms ( This may be essential for the effective counteraction of the damaging effect of the retrobulbar L-NAME application